Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

Clinical trial NCT07535489 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07535489
Sponsor: Nanjing Immunophage Biotech Co., Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Moderately to Severely Active Ulcerative Colitis (UC)

Start date: 2026-07-07
Primary completion: 2028-12-01
Enrollment: 144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.